Skip to main content
Premium Trial:

Request an Annual Quote

Round and Round They Go

Premium

According to a new study published in Lancet Oncology by researchers at MD Anderson Cancer Center, an existing blood test could help clinicians determine whether patients with surgically removed early-stage breast tumors could see their disease return, says Miriam Falco at CNN's The Chart blog. The researchers took blood samples from 302 chemotherapy-naïve women with stage one, two, or three breast cancer before surgery, and found that the women with even one circulating tumor cell in a small blood sample had a four-times greater chance of death than the women with no CTCs in their sample, Falco says. Women with three or more tumor cells in their blood samples had an 11-times higher risk of death. Normally, a lymph-node biopsy is required to determine a woman's risk for recurrence. If the results of this trial are validated in larger groups of women, it may lead to the development of a new and less invasive screening method for breast cancer patients, she adds.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.